These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 19307996)
1. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996 [TBL] [Abstract][Full Text] [Related]
2. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Amato RJ; Malya R; Rawat A Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301 [TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. Amato RJ; Hernandez-McClain J; Henary H Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711 [TBL] [Abstract][Full Text] [Related]
6. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558 [TBL] [Abstract][Full Text] [Related]
8. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. ; Celis E Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944 [TBL] [Abstract][Full Text] [Related]
9. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370 [TBL] [Abstract][Full Text] [Related]
10. Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence. Hemrajani RH; Kim KB; Amos WR; Mann DE Melanoma Res; 2007 Aug; 17(4):257-9. PubMed ID: 17625458 [No Abstract] [Full Text] [Related]
12. A phase I study of the GM-CSF antagonist E21R. Olver IN; Hercus T; Lopez A; Vadas M; Somogyi AA; Doyle I; Foster DJ; Keefe D; Taylor A; Brown M; To LB; Cole J; Rawling T; Cambareri B; Myers M; Olszewski N; Bastiras S; Senn C; Hey A; Verma M; Wigley P Cancer Chemother Pharmacol; 2002 Sep; 50(3):171-8. PubMed ID: 12203098 [TBL] [Abstract][Full Text] [Related]
13. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Vestermark LW; Larsen S; Lindeløv B; Bastholt L Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876 [TBL] [Abstract][Full Text] [Related]
15. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Eisen T; Trefzer U; Hamilton A; Hersey P; Millward M; Knight RD; Jungnelius JU; Glaspy J Cancer; 2010 Jan; 116(1):146-54. PubMed ID: 19862820 [TBL] [Abstract][Full Text] [Related]
16. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Elias EG; Zapas JL; McCarron EC; Beam SL; Hasskamp JH; Culpepper WJ Cancer Biother Radiopharm; 2008 Jun; 23(3):285-91. PubMed ID: 18593361 [TBL] [Abstract][Full Text] [Related]
17. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340 [TBL] [Abstract][Full Text] [Related]
19. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Dreicer R; Klein EA; Elson P; Peereboom D; Byzova T; Plow EF Urol Oncol; 2005; 23(2):82-6. PubMed ID: 15869991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]